In the capital, New Delhi, we run a clinic for victims of sexual and gender-based violence, offering round-the-clock care. In December, we organised a national-level symposium calling for better access to medical and psychological care for victims.
Throughout the year, we provided mental health and psychosocial support to people affected by the conflict in Kashmir, and ran mobile clinics offering basic healthcare to communities in remote areas of Chhattisgarh.
In Mumbai, MSF’s clinic focuses on treating complex cases of DR-TB, including extensively drug-resistant forms of the disease, with innovative drug combinations. For children under five, we implement all-oral regimens, thereby avoiding the need for painful injections.
In addition, we are working with the National Tuberculosis Elimination Programme and Municipal Corporation of Greater Mumbai to reduce the high TB incidence and death rates in the area. Our team co-manages a DR-TB centre in a public hospital, and we support diagnosis, treatment, counselling, health promotion and follow-up in general healthcare facilities.
In 2022, we also continued treating patients enrolled in the endTB clinical trial, with the aim of generating more evidence for shorter, more tolerable, injection-free treatments for multidrug-resistant TB.
Our project in Manipur implements a person-centred care approach for people living with HIV, TB, DR-TB and hepatitis C. We transferred many of our stable HIV patients to Ministry of Health facilities, enabling us to focus on those with co-infections and complications. We also run a one-stop care centre offering comprehensive services for intravenous drug users.
In one of India’s poorest states, Bihar, we provide both lifesaving and palliative care to patients living with advanced HIV.
Our toll-free telemedicine helpline supports diabetes patients to manage their condition. India has the second-highest burden of diabetes globally, and the prevention and management of the disease, as well as its associated complications, remain a huge challenge.